← Leaderboards
Domenico Tortorella
Mount Sinai School Of Medicine Of Nyu
$11,580,055
Attributed
$11,997,623
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,997,623 · 15
By mechanism
R01$5,048,002 · 4
T32$2,631,123 · 1
R21$1,862,460 · 4
R56$1,367,922 · 2
R24$835,137 · 1
R03$252,979 · 3
Top collaborators
- James A Duty1 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Anne Moscona$28,223,876
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventCytomegalovirusVirusInfectionTransplant RecipientsCellsMorbidity - Disease RateCongenital AbnormalityProteinsCytomegalovirus InfectionsHerpesviridaeViralNewborn InfantComplexImmunocompromised HostAffectPharmaceutical PreparationsAcquired Immunodeficiency SyndromeViral ProteinsAutoimmune DiseasesCardiovascular DiseasesGenerationsGanciclovirMutant
Grant awards (37)
Repository of Monoclonal Antibodies (RoMA) against Hamster and Guinea Pig Proteins$835,137
R24 · FY2025 · AI · contact PI
Novel antiviral agents targeting early stage CMV replication$696,985
R01 · FY2025 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$464,705
T32 · FY2025 · AI · contact PI
Optimization of novel inhibitors of human cytomegalovirus$683,995
R56 · FY2024 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$455,803
T32 · FY2024 · AI · contact PI
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination$683,927
R56 · FY2023 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$448,942
T32 · FY2023 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$438,723
T32 · FY2022 · AI · contact PI
Identification of human cytomegalovirus life cycle stage-specific therapeutics$396,177
R01 · FY2022 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$414,307
T32 · FY2021 · AI · contact PI
Identification of human cytomegalovirus life cycle stage-specific therapeutics$396,177
R01 · FY2021 · AI · contact PI
Delineating the mechanism and inhibitory capacity of CMV neutralizing antibodies$211,088
R21 · FY2021 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$408,643
T32 · FY2020 · AI · contact PI
Identification of human cytomegalovirus life cycle stage-specific therapeutics$396,177
R01 · FY2020 · AI · contact PI
Delineating the mechanism and inhibitory capacity of CMV neutralizing antibodies$253,463
R21 · FY2020 · AI · contact PI
Identification of human cytomegalovirus life cycle stage-specific therapeutics$413,552
R01 · FY2019 · AI · contact PI
Anti-drug Conjugates That Target Human Cytomegalovirus Infected Cells$204,380
R21 · FY2019 · AI · contact PI
Anti-drug Conjugates That Target Human Cytomegalovirus Infected Cells$261,279
R21 · FY2018 · AI · contact PI
Development of biologics targeting human cytomegalovirus envelope proteins$211,875
R21 · FY2018 · AI · contact PI
Development of biologics targeting human cytomegalovirus envelope proteins$254,250
R21 · FY2017 · AI · contact PI
Assay development to discover therapeutics against human cytomegalovirus$334,719
R01 · FY2015 · AI · contact PI
Functional screening for neutralizing antibodies targeting CMV entry factors$211,875
R21 · FY2015 · AI · contact PI
Assay development to discover therapeutics against human cytomegalovirus$337,101
R01 · FY2014 · AI · contact PI
Functional screening for neutralizing antibodies targeting CMV entry factors$254,250
R21 · FY2014 · AI · contact PI
Assay development to discover therapeutics against human cytomegalovirus$289,797
R01 · FY2013 · AI · contact PI
Identification of novel inhibitors targeting entry of human cytomegalovirus$41,104
R03 · FY2013 · DA · contact PI
Identification of Inhibitors that Stabilize ER Degradation Substrates$42,375
R03 · FY2012 · MH · contact PI
Identification of novel inhibitors targeting entry of human cytomegalovirus$42,375
R03 · FY2012 · DA · contact PI
Identification of Inhibitors that Stabilize ER Degradation Substrates$42,375
R03 · FY2011 · MH · contact PI
Down-regulation of MHC class l molecules by HCMV US2$381,127
R01 · FY2009 · AI · contact PI
Down-regulation of MHC class l molecules by HCMV US2$33,900
R01 · FY2009 · AI · contact PI
Down-regulation of MHC class l molecules by HCMV US2$381,127
R01 · FY2008 · AI · contact PI
Down-regulation of MHC class l molecules by HCMV US2$321,434
R01 · FY2007 · AI · contact PI
Down-regulation of MHC class l molecules by HCMV US2$50,545
R01 · FY2007 · AI · contact PI
Down-regulation of MHC class l molecules by HCMV US2$331,034
R01 · FY2006 · AI · contact PI
Down-regulation of MHC class l molecules by HCMV US2$288,150
R01 · FY2005 · AI
Luminescent assay:ER dislocation inhibitors (RMI)$84,750
R03 · FY2004 · NS